Overview

A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of long-term treatment with ontamalimab in participants with moderate to severe Ulcerative Colitis (UC) or Crohn's disease (CD)
Phase:
Phase 3
Details
Lead Sponsor:
Shire